Clinical Trials
26 trialsIbrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Evaluating Different Doses of Orelabrutinib in MCL
InnoCare Pharma Inc.
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
Kosin University Gospel Hospital
AIM
Peter MacCallum Cancer Centre, Australia
FIL_KLIMT
Fondazione Italiana Linfomi - ETS
Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
The First Affiliated Hospital of Soochow University
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma
Sun Yat-sen University
A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
MAN2
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
National Cancer Institute (NCI)
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Korea Cancer Center Hospital
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
National Cancer Institute (NCI)
HD-MCL2003
Heidelberg University
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Medical University of Vienna